The briefing
Two Phase 3 studies in Chinese participants found tenofovir alafenamide offers comparable antiviral efficacy to tenofovir disoproxil fumarate with improved renal and bone safety. The results reinforce TAF as a safer long‑term option for chronic hepatitis B management.
Original headline
Long-term study supports tenofovir alafenamide for chronic hepatitis B